Loading
Tryptophan and Brain Disorders / Maternal Mental Health During Pregnancy and Postpartum / Treatment of Major Depression · Journal article
Mental Health Weekly · August 31, 2026
A consensus or society position rather than new primary data.
This is a narrative review in JAMA Psychiatry offering expert guidance that SSRIs pose little or no risk for serious adverse maternal and fetal outcomes when the effects of depression itself are accounted for. The review emphasizes that clinicians should weigh medication safety against documented risks of untreated maternal depression during pregnancy, but does not present new primary data or a systematic analysis.
Narrative review. Pregnant women with depression. Intervention: SSRI treatment during pregnancy. Compared with: Untreated depression during pregnancy.
SSRIs appear to pose little or no risk for the most serious adverse outcomes for mothers and their children when effects of depression itself are separated from medication effects.
Specific adverse outcomes assessed and their absolute or relative risks are not detailed. SSRIs appear to pose little or no risk for the most serious adverse outcomes for mothers and their children when effects of depression itself are separated from medication effects.
Clinicians should consider this expert guidance when counseling pregnant patients with depression about SSRI treatment, recognizing that the risks of untreated illness must be weighed against medication exposure. The message emphasizes that SSRI safety concerns should not be overstated relative to established harms of depression in pregnancy.
A narrative review in a high-impact journal synthesizing expert consensus on SSRI safety in pregnancy, offering clinical guidance rather than reporting new primary data.
As stated by the source record.
Clinicians should consider this expert guidance when counseling pregnant patients with depression about SSRI treatment, recognizing that the risks of untreated illness must be weighed against medication exposure. The message emphasizes that SSRI safety concerns should not be overstated relative to established harms of depression in pregnancy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Mental health experts are urging clinicians to place greater emphasis on treating depression during pregnancy, emphasizing that concerns about antidepressant exposure should be weighed against the well‐documented risks of untreated maternal illness. A new JAMA Psychiatry review concludes that when the effects of depression itself are separated from those of medication, selective serotonin reuptake inhibitors (SSRIs) appear to pose little or no risk for the most serious adverse outcomes for mothers and their children.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.